Publication AWA
At the Public Information Bulletin of the Agency for Health Technology Assessment and Tarification (AWA) has published reviews analyses for the evaluation of reimbursement applications:
- Columvi (glofitamabum) for the treatment of patients with B-cell lymphomas
- Crysvita (burosumabum) for the treatment of patients with X-linked hypophosphatemia (XLH)
- Itulazax (betula verrucosa), sublingual lyophilisate for the treatment of allergic rhinitis and/or conjunctivitis
- Legrex (ticagrelorum) for the prevention of cardiovascular events in adult patients: with acute coronary syndrome (ACS)
- Legrex (ticagrelorum) in combination with acetylsalicylic acid (ASA) for the prevention of cardiovascular events in adult patients: with a history of myocardial infarction (heart attack) and a high risk of cardiovascular events
We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.
